UK medical cannabis registry showed improvements in fibromyalgia patients' quality of life
Analysis of the UK Medical Cannabis Registry found that fibromyalgia patients prescribed cannabis-based medicinal products showed significant improvements in validated quality-of-life measures over at least one month of treatment.
Quick Facts
What This Study Found
Patients prescribed cannabis-based medicinal products for fibromyalgia showed statistically significant improvements in patient-reported outcome measures (PROMs) for health-related quality of life after at least one month of treatment.
Key Numbers
UK Medical Cannabis Registry patients with fibromyalgia. Minimum 1 month of CBMP treatment. Statistically significant improvements in validated PROMs (p<0.050).
How They Did This
Retrospective analysis of the UK Medical Cannabis Registry. Identified patients prescribed cannabis-based medicinal products (CBMPs) for fibromyalgia with minimum one month of follow-up. Assessed changes in validated PROMs and adverse event incidence.
Why This Research Matters
Fibromyalgia has limited treatment options and significantly impairs quality of life. Real-world registry data from the UK provides additional evidence beyond clinical trials for the potential role of medical cannabis.
The Bigger Picture
Medical cannabis registries represent a middle ground between clinical trials and anecdotal reports. The UK registry data adds to the growing body of real-world evidence suggesting fibromyalgia patients may benefit from cannabis-based treatments.
What This Study Doesn't Tell Us
Registry data without a control group. Patients self-selected into treatment. Placebo effect cannot be ruled out. Short minimum follow-up (1 month). Heterogeneous cannabis products prescribed. May not generalize to other healthcare systems.
Questions This Raises
- ?Which specific cannabis-based formulations show the best outcomes for fibromyalgia?
- ?Do improvements persist beyond the initial treatment period?
Trust & Context
- Key Stat:
- Significant improvements in validated quality-of-life measures (p<0.050)
- Evidence Grade:
- Real-world registry data with validated outcomes. Lack of control group and self-selection limit causal inference.
- Study Age:
- Published 2023.
- Original Title:
- Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry.
- Published In:
- Brain and behavior, 13(7), e3072 (2023)
- Authors:
- Wang, Claire, Erridge, Simon(22), Holvey, Carl(10), Coomber, Ross, Usmani, Azfer, Sajad, Mohammed, Guru, Rahul, Holden, Wendy, Rucker, James J, Platt, Michael W, Sodergren, Mikael H
- Database ID:
- RTHC-05014
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Does medical cannabis help fibromyalgia in real patients?
This UK registry analysis found fibromyalgia patients reported significant improvements in quality of life after starting cannabis-based treatments. However, without a control group, some improvement could be due to placebo effect, natural symptom fluctuation, or other concurrent treatments.
What is the UK Medical Cannabis Registry?
It is a database tracking patients prescribed cannabis-based medicinal products by specialist clinicians in the UK. It collects standardized outcome measures and adverse events, providing real-world data on how medical cannabis performs outside clinical trials.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05014APA
Wang, Claire; Erridge, Simon; Holvey, Carl; Coomber, Ross; Usmani, Azfer; Sajad, Mohammed; Guru, Rahul; Holden, Wendy; Rucker, James J; Platt, Michael W; Sodergren, Mikael H. (2023). Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry.. Brain and behavior, 13(7), e3072. https://doi.org/10.1002/brb3.3072
MLA
Wang, Claire, et al. "Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry.." Brain and behavior, 2023. https://doi.org/10.1002/brb3.3072
RethinkTHC
RethinkTHC Research Database. "Assessment of clinical outcomes in patients with fibromyalgi..." RTHC-05014. Retrieved from https://rethinkthc.com/research/wang-2023-assessment-of-clinical-outcomes
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.